Short-term side effects of low dose valproate monotherapy in epileptic children: a prospective study by Nasr Esfahani, Parisa et al.
37Iran J Child Neurol. Spring 2019 Vol. 13 No. 2
ORIGINAL ARTICLE
How to Cite This Article: Nasr Esfahani P , Nasiri J , Badihian SH , Yaghini O . Short-Term Side Effects of Low Dose Valproate Monotherapy in 
Epileptic Children: A Prospective Study. Iran J Child Neurol. Spring 2019; 13(2): 37-46




Considering the common use of valproate among children, we investigated the 
short-term side-effects of low dose valproate monotherapy in epileptic children.
Methods
In this prospective study, 209 epileptic children (48.3% male, mean age: 
7.02 ± 3.13 yr) on low therapeutic dose of valproate monotherapy (20-30 
mg/kg/d) were enrolled during 2014-2015 in Isfahan Pediatric Neurology 
Clinic, Isfahan University of Medical Sciences, Isfahan, Iran and side-
effects were evaluated through frequent clinical visits and laboratory tests 
during 6 months of valproate therapy.
Results
Weight gain was reported in 53.1% of patients. Decreased appetite was seen 
in 11% of patients, more frequent in younger cases (P=0.006). Abdominal 
pain, nausea/vomiting, diarrhea, and constipation were reported in 16.3%, 
2.4%, 1.4%, and 1% of patients, respectively. Headache, tremor, dizziness, 
abnormal color vision, myoclonus, and bruxism were seen in 5.7%, 1.4%, 
1%, 1%, 1%, and 0.5% of patients, respectively. Enuresis, hair loss, and 
skin rash were reported in 8.1%, 6.7%, and 0.5% of patients, respectively. 
Thrombocytopenia, impaired liver function tests, and leukopenia occurred 
in 1%, 1%, and 0.5% of patients, respectively.
Conclusion
Low dose valproate monotherapy may cause numerous side-effects, 
mostly not life-threatening and requiring no action. Beside other reported 
complications, we observed decreased appetite (among younger patients), 
enuresis, and abnormal color vision which are only briefly discussed in the 
literature and need to be addressed more.
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Introduction
Valproate (VPA) is a broad-spectrum antiepileptic 
drug, used for treatment of certain types of 
seizures since 1970 (1). It can also be used in other 
conditions including some psychiatric disorders 
and prophylaxis of migraine (1). Epilepsy is a 
common disease among children and adolescents. 
Approximately 10.5 million children under 15 yr 
(about 0.8%) suffer from active epilepsy, of whom 
more than 80% live in developing countries (2). 
Although VPA is an old antiepileptic drug, it is still 
widely administered for epileptic patients, since it 
is favorably safe and inexpensive (3).
VPA may cause transient and non-hazardous side 
effects as well as serious and life-threatening side 
effects. Transient and non-hazardous side effects 
include weight gain, drowsiness, transient hair loss, 
tremor, increased gamma-glutamyl transferase, 
nausea, headache, and other complications (1, 
4). Serious side effects include hepatotoxicity, 
encephalopathy, coagulation disorders, pancreatitis, 
and bone marrow suppression (1, 5, 6). Complications 
of VPA are also classified as gastrointestinal, 
neurological, metabolic and endocrine, hematologic, 
pulmonary, renal, dermatologic, mitochondrial, and 
hepatic adverse events (1). These complications may 
be associated with factors such as age and dose (1).
Although several studies were conducted on the 
subject, no study was designed to evaluate these 
complications in a pediatric population on low 
dose VPA as monotherapy. We aimed to investigate 
the short-term complications of low dose VPA in a 
pediatric population through frequent interviews, 
clinical visits, and lab tests during a 6-month 
period of therapy.
Materials & Methods
This cross-sectional prospective study performed 
during 2014-2015 in Isfahan Pediatric Neurology 
Clinic, Isfahan University of Medical Sciences, 
Isfahan, Iran. Patients ranging from 2 to 15 yr 
old, with diagnosis of epilepsy supposed to start 
low therapeutic dose of VPA (20-30 mg/kg/d) 
as monotherapy were included in the study. 
The exclusion criteria were defined as any other 
comorbid disease or medical condition including 
chronic hepatic disease, chronic renal disease, 
metabolic syndromes, diabetes, progressive 
neurological diseases, diseases of digestive system, 
and coagulation disorders; experiencing worsened 
seizures after starting VPA; needing higher doses 
of VPA; taking any other medication affecting 
body weight. 
The study was approved by the regional bioethics 
committee of Isfahan University of Medical 
Sciences and informed consent was obtained from 
all patients or their parents.
VPA was started for patients with the decision 
of pediatric neurologists and based on the recent 
guidelines on treatment of epilepsy (7). After 
recruitment, a thorough history was taken from 
patients and they underwent complete physical 
and neurological examination. We designed a data 
collection questionnaire which included patients’ 
characteristics and demographic data, initial 
weight, seizure type, prescribed dose of VPA, and 
possible side effects of the drug (based on previous 
studies), including weight gain, change in appetite 
(according to parents’ evaluation), abdominal 
pain, nausea/vomiting, headache, enuresis, hair 
loss (diffuse reduction of hair defined as losing 
more than 100 hairs daily, evaluated by parents), 
diarrhea, constipation, tremor, skin rash, dizziness, 
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abnormal color vision (sensible changes in the 
color vision or dominance of certain colors stated 
by the patient), bruxism, and myoclonus. To 
evaluate weight gain, we weighed patients at two 
time-points: before taking VPA, and after 6 months 
of taking VPA. As we expected no considerable 
changes in the children’s height and in turn, their 
body mass index, we calculated weight-for-age 
Z-score for each subject in these two time-points, 
using national z-score tables for boys and girls. 
Two amounts were compared to each other then, 
and increased z-score for ≥1 unit was considered 
as weight gain (8).
Blood samples were also taken to evaluate complete 
blood count with differentials (CBC-diff), serum 
glutamic oxaloacetic transaminase (SGOT), and 
serum glutamic pyruvic transaminase (SGPT) at 
four time-points: before starting the medication, 1 
month, 3 months, and 6 months after starting the 
medication. Blood samples were obtained between 
8 and 9 in the morning, after an overnight fast and 
before breakfast. Platelet count <150,000 /µL was 
considered as thrombocytopenia, WBC <4000 /µL 
was considered as leukopenia and increased SGOT 
and SGPT for more than two times were considered 
as increased liver enzymes. In patients with serious 
side effects, drug intolerance, and impaired lab 
tests, VPA was discontinued and was replaced 
with another drug. All the observed adverse drug 
reactions were rated using Naranjo scale (9) into 
one of the categories of highly probable, probable, 
possible, and doubtful. Naranjo scale determines 
whether an adverse drug reaction is actually due to 
the medication or it is caused by other factors. This 
scale evaluates the probability of a complication 
through 10 questions (9).
We reported data using descriptive statistics 
for frequencies and analytical statistics (Mann-
Whitney test) for analysis of possible differences, 
using SPSS 19 (Chicago, IL, USA). A P-value less 
than 0.05 was considered as significant.
Results
Overall, 229 patients were included initially 
and 20 of them were excluded (13 patients with 
worsened seizures and 7 cases who needed higher 
doses of VPA). Of the remained cases, 101 patients 
(48.3%) were male and the mean age (standard 
deviation [SD]) was 7.02 (3.13). Most patients 
had generalized seizures (75.6%) followed by 
absence seizures (9.6%), partial seizures (8.6%), 
and myoclonic seizures (6.2%).
Adverse drug reactions and their association 
with age are summarized in Table 1. Weight gain 
was seen in 111 patients (53.1%) while 33% of 
patients reported increased appetite and 11% of 
them reported decreased appetite. Older patients 
experienced increased appetite more frequently 
(P=0.006). Abdominal pain was reported in 16.3% 
of patients. It was mostly transient and lead to VPA 
discontinuation in none of the cases.
Twelve patients (5.7%) complained of headache, 
seen more in older ages (P<0.001). Enuresis 
and hair loss were reported in 17 (8.1%) and 14 
(6.7%) patients respectively. Tremor and diarrhea 
were seen in 3 (1.4%) patients, and tremor was 
seen more in older ages (P=0.017). Only 2 
patients (0.1%) presented one of the symptoms of 
dizziness, constipation, abnormal color vision, and 
myoclonus and one patient (0.5%) experienced 
skin rash or bruxism. Abnormal color vision was 
reversed by drug discontinuation.
Regarding patients’ lab tests, 2 cases (1%) 
developed thrombocytopenia, one patient (0.5%) 
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had leukopenia, and in 2 patients had (1%) impaired 
liver function tests. In general, side effects lead 
to drug discontinuation in 12 patients, including 
2 patients with thrombocytopenia, 1 patient with 
leukopenia, 7 patients with drug intolerance, and 2 
patients with abnormal color vision.
Regarding all the side effects (except appetite 
change), 101 patients (48.3%) experienced one 
side effect, 29 patients (13.9%) experienced two 
side effects, 13 patients (6.2%) experienced three 
side effects and 3 patients (1.5%) experienced 
four or five side effects. Therefore, only 30.1% of 
patients experienced no side effects.
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Table 1. Complications of valproate and their association with patients’ age
Category Subcategory Frequency (%) Age (Mean ± SD) P-value Naranjo scale
Weight gain Yes 111 (53.1) 7.29 ± 3.03 0.121 Probable ADR
No 98 (46.9) 6.79 ± 3.19
Appetite Increased 69 (33) 8 ± 3.28 0.006 Probable ADR
Decreased 23 (11) 6.72 ± 2.08 Possible ADR
No change 117 (56) 6.51 ± 3.10
Abdominal pain Yes 34 (16.3) 7.75 ± 2.73 0.54 Probable ADR
No 175 (83.7) 6.88 ± 3.20
Nausea/vomiting Yes 5 (2.4) 9.20 ± 4.09 0.160 Probable ADR
No 204 (97.6) 6.97 ± 3.10
Headache Yes 12 (5.7) 10.50 ± 3.15 <0.001 Probable ADR
No 197 (94.3) 6.81 ± 3.01
Enuresis Yes 17 (8.1) 7 ± 3.15 0.895 Possible ADR
No 192 (91.9) 7.03 ± 3.14
Hair loss Yes 14 (6.7) 8.25 ± 3.31 0.142 Probable ADR
No 195 (93.3) 6.94 ± 3.11
Diarrhea Yes 3 (1.4) 6.67 ± 1.53 0.912 Probable ADR
No 206 (98.6) 7.03 ± 3.15
Tremor Yes 3 (1.4) 12 ± 2 0.017 Probable ADR
No 206 (98.6) 6.95 ± 3.09
Skin rash Yes 1 (0.5) 2 0.029 Probable ADR
No 208 (99.5) 7.05 ± 3.12
Dizziness Yes 2 (1) 7.50 ± 0.71 0.540 Probable ADR
No 207 (99) 7.02 ± 3.15
Constipation Yes 2 (1) 5 0.340 Probable ADR
No 207 (99) 7.04 ± 3.14
Bruxism Yes 1 (0.5) 7 0.871 Possible ADR
No 208 (99.5) 7.02 ± 3.14
Myoclonus Yes 2 (1) 8.50 ± 4.95 0.596 Possible ADR
No 207 (99) 7.01 ± 3.13
Abnormal color vision Yes 2 (1) 6.5 ± 2.12 0.981 Possible ADR
No 207 (99) 7.03 ± 3.15
Thrombocytopenia Yes 2 (1) 5.5 ± 0.71 0.520 Probable ADR
No 207 (99) 7.04 ± 3.15
Leukopenia Yes 1 (0.5) 15 0.029 Probable ADR
No 208 (99.5) 6.99 ± 3.09
Increased liver enzymes Yes 2 (1) 4.5 ± 0.71 0.199 Probable ADR
No 207 (99) 7.05 ± 3.14
SD: standard deviation; ADR: adverse drug reaction
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Discussion
Weight gain is one of the common complications 
of VPA seen in 53.1% of our patients, without any 
association with age. A study on Iranian children 
showed weight gain due to VPA in 40% of patients 
(10), however, another study reported weight gain 
in 58% of their cases (11). A negative correlation 
between weight gain and duration of treatment was 
reported before (12). weight gain is seen more in 
epileptic patients over 10 yr old (13). In contrast, 
no association was found between weight gain and 
age, gender, and drug dose in another study (14), 
which is also consistent with our findings.
In a clinical trial on epileptic children, increased 
appetite was reported in all of their subjects 
with marked weight gain  (15).  Increased and 
decreased appetite were seen in 33% and 11% of 
our patients, respectively. We found that patients 
with increased appetite are older than those with 
decreased or unchanged appetite. Based on our 
results, decreased appetite may be a complication 
of low dose VPA particularly in younger ages, 
however, we believe that evaluation of appetite 
may not be precise enough in our study since it 
was evaluated by parents. Decreased appetite has 
not been reported in previous studies and needs to 
be investigated more in the future, especially in 
younger patients. 
Other gastrointestinal side effects in our study 
included abdominal pain (16.3%), nausea/
vomiting (2.4%), constipation (1%), and diarrhea 
(1.4%). Gastrointestinal complications are known 
as common side effects of VPA occurring in up 
to 50% of patients (1, 4, 16). These symptoms 
are usually transient and require no intervention 
(4). Sudden onset of abdominal pain may be due 
to acute pancreatitis, which is an uncommon but 
serious side effect of VPA (1). We had no report of 
pancreatitis among our cases.
Neurological adverse effects reported among our 
cases were as follows: Dizziness (1%), headache 
(5.7%), tremor (1.4%), abnormal color vision 
(1%), myoclonus (0.5%), and bruxism (0.5%). 
We found headache more in older patients. Older 
patients are more capable of expressing their 
headache and this may be a factor affecting our 
results. Dizziness and headache are suggested as 
VPA side effects in previous studies (17). Tremor 
is commonly reported as a side effect of VPA (17) 
occurring in 1%-6% of patients (4) and is known to 
be dose dependent (18). Bruxism and myoclonus 
are rarely reported in the literature as side effects 
of VPA (1, 19).
We found enuresis in 8.1% of our patients. 
Enuresis due to VPA intake is less being addressed 
in the literature (18). In a study, 72 epileptic 
patients ranging from 2 to 15 yr were on long-
term VPA therapy and reported enuresis in 17 of 
them (24%), which stopped after discontinuation 
of the drug. Age was the only factor introduced 
as the predicting factor for enuresis in this study 
(18). Moreover, Egger and Brett reported enuresis 
in 7% of their study group (100 subjects) (20). 
We confirm previous findings on the frequency of 
enuresis after VPA therapy, but after a short-term 
period, however, we found no association between 
enuresis and age. Enuresis was a new finding in our 
patients and they did not have history of enuresis 
due to seizures.
Hair loss was reported by 6.7% of our patients. 
Several studies have addressed the possible effects 
of VPA on hair growth, such as alopecia, thinning 
hair, and color change (4, 21). The occurrence of 
this condition has been reported from 3.5% to 11% 
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in previous studies (21). Hair loss due to VPA is 
usually scattered, without any scars, occurring 3 to 
6 months after starting VPA, and is suggested to 
be associated with higher doses of the medication 
in a few studies (21). Only one case (0.5%) 
complained of skin rash in our study. Skin rash is a 
rarely reported complication of VPA, mostly seen 
in combination therapies and is disappeared after 
drug discontinuation (4, 22).
VPA might impair color perception significantly 
(23). A study on adolescents on VPA monotherapy 
showed that VPA can significantly affect central 
and para-central color vision after a short-term 
period (24). Ophthalmologic examination of 
these patients is recommended in case ophthalmic 
symptoms develop (24). Two of our patients (1%) 
complained of abnormal color vision during their 
treatment. The complication was reversed by 
VPA discontinuation. Our patients described their 
condition as seeing objects with abnormal colors 
or dominancy of certain colors. Considering the 
reversibility of these symptoms, it seems not to be 
a serious complication of VPA.
We found thrombocytopenia in 1% of our 
patients. Thrombocytopenia is a dose-dependent 
complication of VPA (1, 4). This condition has 
been reported in a wide range of 1% to 32% in 
patients with different age groups and is known 
as the most common hematologic side effect of 
VPA (1, 18, 25, 26). Thrombocytopenia is reported 
more frequently due to multiple drug treatment, 
being female, and initial thrombocytopenia (27). 
Children are more prone to thrombocytopenia 
because of using higher doses of the drug compared 
to adults. Reduction or discontinuation of VPA 
results in increasing platelet counts in the next few 
days in these patients (25).
One of our patients (0.5%) developed leukopenia 
during the study. Leukopenia is rarely reported as 
a complication of VPA and is reversible by drug 
discontinuation and happens more in combination 
therapies (28). Bone marrow suppression and 
production of antibodies against thrombocytes 
may be responsible for decrease in blood cell lines 
(1). Increased liver enzymes were observed in 1% 
of our patients. Elevation of serum transaminases 
is a common and mainly reversible side effect of 
VPA, although it may develop to more severe and 
irreversible conditions such as severe hepatotoxicity 
(1, 4, 5, 29). Hepatotoxicity is reported to happen 
more in younger ages (30) and higher administered 
doses of VPA (29).
In this study, we had some limitations that should be 
noted. First, this study was open and uncontrolled. 
Therefore, we could not compare the frequency of 
complications with the normal population which 
makes it hard to distinguish adverse events from 
adverse effects. Second, some complications, such 
as hair loss and color vision, were evaluated based 
on parents’ or patients’ evaluation, while measuring 
them with more objective tools (for example 
dermatologic or ophthalmologic examination) 
might change the results. These results may be 
underestimated or overestimated in our study, 
based on parents’ precision and their obsession 
with their children. Third, we studied subjects who 
were on low dose VPA monotherapy, while VPA 
may develop more side effects on polytherapy 
and higher doses. Forth, there are some other 
side effects of VPA including oligomenorrhea in 
female adolescents and decreased serum levels of 
vitamin D not measured in this study. Despite these 
limitations, this is the first study that evaluates side 
effects of low dose VPA monotherapy in epileptic 
children in a prospective design.
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In conclusion, low dose VPA monotherapy may 
cause numerous side effects, however, most of 
them are not dangerous and life-threatening. We 
reported decreased appetite especially in patients 
with younger ages which needs to be investigated 
more in future studies. Moreover, we addressed 
enuresis and abnormal color vision briefly 
discussed in the literature and need to be studied 
more. Further studies with larger study population 
and longer follow up period are recommended to 
evaluate our findings.
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